FDA Warning With Two New Hepatitis C Medications

illustrated heart

A potentially life-threatening slowing of the heart can occur when the common heart drug amiodarone is taken with new hepatitis C medications, the U.S. Food and Drug Administration warns.

Get The LATEST Articles Straight To Your Inbox!

 

The dangerous slowing of the heart — called symptomatic bradycardia — can occur when amiodarone is taken with the hepatitis C drugs Harvoni (ledipasvir/sofosbuvir) or Sovaldi (sofosbuvir) and combined with another direct-acting antiviral for the treatment of hepatitis C.